NeuroDerm Ltd. shares surged almost 20% in premarket trade Tuesday, after the company announced promising results from a trial of a treatment for Parkison's disease. The Israeli company said continuous, subcutaneous delivery of two liquid product candidates had a positive effect on plasma levels, suggesting the high dose version that is aimed at severe sufferers of the disease may be an effective alternative to current treatments that require surgery. The higher dose candidate, known as ND0612H, "is designed to be delivered continuously, thus we believe it should offer a simple and effective treatment option that will minimize the need for surgical intervention in advanced Parkinson's patients," Sheila Oren, vice president of clinical and regulatory affairs at the company, said in a statement. Shares of NeuroDerm, which went public in November, are down 15.2% on the month, while the S&P 500 has gained 1.1%.
Copyright © 2014 MarketWatch, Inc.
Continue Reading Below